Preferred Label : Belimumab;

NCIt synonyms : Immunoglobulin G1, anti-(Human Cytokine BAFF) (Human Monoclonal LymphoStat-B Heavy Chain), Disulfide with Human Monoclonal LymphoStat-B lambda-chain, Dimer;

NCIt definition : A fully human IgG1 monoclonal antibody directed against B-Lymphocyte stimulator protein (BlyS or TNFSF13B) with potential immunomodulating activity. Belimumab specifically recognizes and inhibits the biological activity of BlyS, thereby preventing the binding of BlyS to B-lymphocytes. This inhibits the maturation of B-lymphocytes and may induce apoptosis in B-lymphocytes. In addition, it may decrease B-lymphocyte proliferation and/or survival. BlyS, a member of TNF family supporting B-lymphocyte maturation and survival, has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies.;

UNII : 73B0K5S26A;

CAS number : 356547-88-1;

Drug name : LymphoStat-B; Benlysta;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.rheuma-net.ch/fr/doc/belimumab-1/viewdocument/358
2024
Switzerland
guideline
belimumab
Belimumab
belimumab
Background Treatment
belimumab

---
Nous contacter.
30/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.